Advocacy intelligence hub — real-time data for patient organizations
National Cancer Institute (NCI) — PHASE1
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
POTELIGEO
(mogamulizumab)Orphan drugstandardKyowa Kirin Pharmaceutical Development Inc.
Chemokine Receptor Type 4 Interaction [EPC]
12.1 Mechanism of Action Mogamulizumab-kpkc is a defucosylated, humanized IgG1 kappa monoclonal antibody that binds to CCR4, a G protein-coupled recep...